Here are the DEF 14A proxy statements from OnKure Therapeutics, Inc. (OKUR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification and a major update to its equity plan. Holders of 40,395,480 shares of Class A Common Stock as of April 16, 2026 may vote, one vote per share.
Stockholders will elect three Class II directors (R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers) to terms ending at the 2029 meeting and vote on ratifying KPMG LLP as independent auditor for the year ending December 31, 2026. The meeting will be held online on June 3, 2026 at 9:00 a.m. Eastern Time.
A key item is approval of an amended and restated 2024 Equity Incentive Plan, which would add 3,231,638 shares (about 8% of outstanding shares) to the plan’s reserve, remove the 2,407,100‑share annual cap in the evergreen provision (after a 1:10 reverse split), and introduce a limit on incentive stock options. The board cites dilution from a March 2026 $150.0 million PIPE financing, in which 26,713,638 shares were sold, and the resulting fall of employee ownership below the 25th percentile of peers, as reasons to expand equity capacity to support recruitment, retention and long‑term incentives.